CASI PHARMACEUTICALS, INC.: 10-Q filed 2014-08-14
What CASI PHARMACEUTICALS, INC. reported in its quarterly report filed 2014-08-14 (fiscal Q2 2014): 20 published measures, 48 facts as tagged in accession 0001144204-14-049649.
This filing
- Form
- 10-Q (quarterly report)
- Filed
- 2014-08-14
- Fiscal period
- fiscal Q2 2014
- Accession
- 0001144204-14-049649 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All CASI PHARMACEUTICALS, INC. filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-06-30 | 13,482,751 | USD | |
| At 2013-12-31 | 15,507,551 | USD |
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-06-30 | 12,739,401 | USD | |
| At 2013-12-31 | 14,942,385 | USD |
Cash and cash equivalents
Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-06-30 | 13,079,745 | USD | |
| At 2013-12-31 | 15,131,671 | USD | |
| At 2013-06-30 | 17,222,918 | USD | |
| At 2012-12-31 | 8,049,237 | USD |
Net income or loss
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2014-04-01 to 2014-06-30 | -1,616,281 | USD | 91 |
| 2014-01-01 to 2014-06-30 | -3,067,246 | USD | 181 |
| 2013-04-01 to 2013-06-30 | -1,851,840 | USD | 91 |
| 2013-01-01 to 2013-06-30 | -2,987,727 | USD | 181 |
Capital expenditure payments
Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2014-01-01 to 2014-06-30 | 181,403 | USD | 181 |
| 2013-01-01 to 2013-06-30 | 16,926 | USD | 181 |
Retained earnings or deficit
Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-06-30 | -402,136,854 | USD | |
| At 2013-12-31 | -399,069,608 | USD |
Net property, plant and equipment
Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-06-30 | 240,377 | USD | |
| At 2013-12-31 | 78,142 | USD |
Share-based compensation expense
Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2014-01-01 to 2014-06-30 | 864,262 | USD | 181 |
| 2013-01-01 to 2013-06-30 | 1,164,578 | USD | 181 |
Current assets
Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-06-30 | 13,216,363 | USD | |
| At 2013-12-31 | 15,411,444 | USD |
Current liabilities
Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-06-30 | 743,350 | USD | |
| At 2013-12-31 | 565,166 | USD |
Current accounts payable
Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-06-30 | 573,513 | USD | |
| At 2013-12-31 | 402,456 | USD |
Research and development expense
Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2014-04-01 to 2014-06-30 | 724,493 | USD | 91 |
| 2014-01-01 to 2014-06-30 | 1,284,467 | USD | 181 |
| 2013-04-01 to 2013-06-30 | 836,582 | USD | 91 |
| 2013-01-01 to 2013-06-30 | 1,342,957 | USD | 181 |
Common shares outstanding
Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-06-30 | 27,119,974 | shares | |
| At 2013-12-31 | 27,119,974 | shares |
Additional paid-in capital
Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-06-30 | 422,639,301 | USD | |
| At 2013-12-31 | 421,775,039 | USD |
Other noncurrent assets
Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-06-30 | 26,011 | USD | |
| At 2013-12-31 | 17,965 | USD |
Accrued current liabilities
Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-06-30 | 169,837 | USD | |
| At 2013-12-31 | 162,710 | USD |
Prepaid expenses and other current assets
Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-06-30 | 136,618 | USD | |
| At 2013-12-31 | 279,773 | USD |
General and administrative expense
General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2014-04-01 to 2014-06-30 | 891,917 | USD | 91 |
| 2014-01-01 to 2014-06-30 | 1,783,292 | USD | 181 |
| 2013-04-01 to 2013-06-30 | 1,015,701 | USD | 91 |
| 2013-01-01 to 2013-06-30 | 1,645,603 | USD | 181 |
Change in accounts receivable
The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2014-01-01 to 2014-06-30 | 0 | USD | 181 |
| 2013-01-01 to 2013-06-30 | -669,310 | USD | 181 |
Change in accounts payable
The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2014-01-01 to 2014-06-30 | 171,057 | USD | 181 |
| 2013-01-01 to 2013-06-30 | 94,156 | USD | 181 |
Inspect the source
- Entity
- CASI PHARMACEUTICALS, INC. / CIK 0000895051
- Captured
- SEC response SHA-256
a5465bb63979ec441cdd2d0b7761265dc0541f5ee25dcdffded348a960f99c09
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0000895051.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))